Register
Login:
Share:
Email Facebook Twitter

RNS VIDEO: Reabold Resources #RBD raise £6 million and take stake in Danube Petroleum Watch here

EXCLUSIVE: HemoGenyx are creating blood cancer treatments with US$9 billion market potential


Astrazeneca Regulatory News (AZN)



Regulatory News for Astrazeneca (AZN)


Share Price: 4,881.00Bid: 4,881.00Ask: 4,884.50Change: -3.50 (-0.07%)Faller - Astrazeneca
Spread: 3.50Spread as %: 0.07%Open: 4,889.00High: 4,889.00Low: 4,846.50Yesterday’s Close: 4,884.50





DateSourceHeadlineCategory
15-Dec-17 12:00RNSDirector/PDMR ShareholdingDirectors' Dealings
01-Dec-17 15:00RNSBlock listing Interim ReviewCompany Announcement - General
01-Dec-17 15:00RNSTotal Voting RightsHolding(s) in Company
28-Nov-17 07:00RNSEMA accepts Tagrisso submission for 1st-line nsclcCompany Announcement - General
27-Nov-17 07:00RNSAZ submits Tagrisso in Japan for 1st-line nsclcCompany Announcement - General
15-Nov-17 07:00RNSAZ Fasenra receives FDA approval for severe asthmaCompany Announcement - General
10-Nov-17 11:35RNSBENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMACompany Announcement - General
09-Nov-17 07:00RNSAZN: Year-To-Date and Q3 2017 Results AnnouncementResults and Trading Reports
01-Nov-17 15:00RNSTotal Voting RightsHolding(s) in Company
01-Nov-17 07:03RNSASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEALCompany Announcement - General
01-Nov-17 07:00RNSAstraZeneca tralokinumab update in severe asthmaCompany Announcement - General
31-Oct-17 17:05RNSUS FDA approves AstraZeneca's Calquence for MCLCompany Announcement - General
23-Oct-17 07:05RNSAZ and MSD rapidly advance Lynparza in JapanCompany Announcement - General
23-Oct-17 07:00RNSUS FDA approves Bydureon BCise for type-2 diabetesCompany Announcement - General
18-Oct-17 07:00RNSFDA Priority Review for Lynparza in breast cancerCompany Announcement - General
17-Oct-17 07:00RNSFDA accepts sBLA file for Imfinzi; priority reviewCompany Announcement - General
09-Oct-17 07:00RNSFDA grants Tagrisso BTD for 1st-line EGFR nsclcCompany Announcement - General
02-Oct-17 15:00RNSTotal Voting RightsHolding(s) in Company
26-Sep-17 12:00RNSDirector/PDMR ShareholdingDirectors' Dealings
14-Sep-17 07:00RNSAspen acquires remaining rights to AZ anaestheticsCompany Announcement - General
11-Sep-17 07:00RNSTagrisso potential standard of care in lung cancerCompany Announcement - General
11-Sep-17 07:00RNSIMFINZI superior PFS in Stage III lung cancerCompany Announcement - General
07-Sep-17 12:39RNSCelgene and AZ update on Fusion trial programmeCompany Announcement - General
07-Sep-17 07:00RNSAZ Duaklir improves lung function in COPD patientsCompany Announcement - General
07-Sep-17 07:00RNSAZ tezepelumab cuts exacerbations in severe asthmaCompany Announcement - General
05-Sep-17 07:00RNSDirectorate ChangeExecutive Changes
01-Sep-17 15:00RNSTotal Voting RightsHolding(s) in Company
29-Aug-17 07:00RNSFaslodex gets US FDA OK for expanded use in breastCompany Announcement - General
18-Aug-17 07:00RNSLynparza gets broad FDA approval in ovarian cancerCompany Announcement - General
16-Aug-17 07:00RNSDirectorate ChangeExecutive Changes


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.